BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Marty Chargin

Trader & Market Student of SUPER WINNERS since 1998 | Founder @TickerMonkey | Partner w/ @TMLTrader | Co-Founder TM Data Systems | ERx Gap Course w/ @JPoco722

Hybrid Position/Swing Trader, Cancer Survivor, Father, Brother, Uncle, Wine lover and Windsurfer. All opinions are my own and not investment advice.

BillionToOne Inc. Class A Common Stock (BLLN) Stock Price, Analysis & Trade Signals